Trial Profile

Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL) - (Optimizing Acute Stress Reaction Interventions With TNX-102 SL - OASIS)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 30 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Apr 2026 Planned End Date changed from 1 Sep 2025 to 1 Sep 2026.
13 Apr 2026 Planned primary completion date changed from 1 Sep 2025 to 1 Sep 2026.
21 May 2025 According to a Tonix Pharmaceuticals Holding Corp media release, first patient has been dosed in this trial , trial is sponsored by the University of North Carolina (UNC) and supported by a grant from the U.S. Department of Defense, Topline results from the trial are expected in the second half of 2026

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com